Global Lewy Body Dementia Treatment Market – Industry Trends and Forecast to 2031

Análisis y tamaño del mercado de tratamiento de la demencia por cuerpos de Lewy

El mercado de tratamiento de la demencia con cuerpos de Lewy (DCL) está experimentando un crecimiento significativo, impulsado por varios factores. La creciente prevalencia de la demencia con cuerpos de Lewy, junto con el envejecimiento de la población en todo el mundo, es un impulsor clave del crecimiento del mercado. Además, la creciente conciencia sobre la DCL y los avances en las técnicas de diagnóstico están llevando a la detección y el diagnóstico tempranos, impulsando la demanda de opciones de tratamiento. El mercado se caracteriza por una variedad de opciones de tratamiento, que incluyen medicamentos, terapia y cambios en el estilo de vida. Los medicamentos como los inhibidores de la colinesterasa y los medicamentos para la enfermedad de Parkinson se usan comúnmente para controlar los síntomas de la DCL, como el deterioro cognitivo y los trastornos del movimiento. Las terapias como la fisioterapia , la terapia ocupacional y la terapia del habla pueden ayudar a mejorar la calidad de vida y mantener la función. Los cambios en el estilo de vida, incluido el ejercicio regular y una dieta saludable, también son importantes para controlar los síntomas de la DCL.

El tamaño del mercado global de tratamiento de la demencia con cuerpos de Lewy se valoró en USD 5.66 mil millones en 2023 y se proyecta que alcance los USD 10.71 mil millones para 2031, con una CAGR del 8,30% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado       

Definición de mercado

La demencia por cuerpos de Lewy (DCL) es un trastorno neurológico progresivo que afecta el pensamiento, la memoria y el movimiento. Si bien no existe cura para la DCL, los tratamientos para la demencia por cuerpos de Lewy se centran en controlar los síntomas y mejorar la calidad de vida. El tratamiento generalmente implica una combinación de medicamentos, terapia y cambios en el estilo de vida.    

Dinámica del mercado de tratamiento de la demencia por cuerpos de Lewy

Conductores

• Concientización y diagnóstico crecientes

El aumento de la conciencia sobre la demencia por cuerpos de Lewy (DCL) entre los profesionales de la salud y la población en general es un factor crucial que impulsa el crecimiento del mercado. Con una mayor conciencia, los proveedores de atención médica están más inclinados a identificar los signos tempranos de la DCL, lo que resulta en un diagnóstico e intervención oportunos. El diagnóstico temprano permite el inicio oportuno del tratamiento y las estrategias de manejo, lo que puede ayudar a mejorar la calidad de vida de las personas con DCL. Además, una mayor conciencia entre la población en general puede llevar a que más personas busquen atención médica para los síntomas relacionados con la DCL, lo que contribuye aún más al diagnóstico y tratamiento tempranos. En general, la creciente conciencia sobre la DCL está desempeñando un papel importante en el impulso del crecimiento del mercado.       

• Avances en la investigación médica   

Los investigadores están explorando diversos enfoques para el manejo de la DCL, incluidos nuevos tratamientos farmacológicos, intervenciones en el estilo de vida y terapias no farmacológicas. Estos avances apuntan a las causas fundamentales de la DCL, como las acumulaciones anormales de proteínas en el cerebro, para mejorar el control de los síntomas. Además, la investigación sobre biomarcadores para la DCL está ayudando a mejorar la precisión del diagnóstico y a monitorear la progresión de la enfermedad. Se espera que el progreso continuo en la investigación médica conduzca a tratamientos más efectivos para la DCL, impulsando el crecimiento del mercado al expandir la gama de opciones disponibles para los pacientes y los proveedores de atención médica.

Oportunidades

• Avances tecnológicos  

The field of Lewy body dementia (LBD) treatment has seen remarkable advancements in recent years, particularly in the development of diagnostic tools and treatment modalities. These technological innovations have greatly improved the accuracy of diagnosing LBD, allowing healthcare professionals to detect the disease at earlier stages. Advanced imaging techniques, such as positron emission tomography (PET) scans and magnetic resonance imaging (MRI), have enabled more precise visualization of brain structures and abnormalities associated with LBD. Furthermore, the application of biomarkers and genetic testing has enhanced diagnostic precision. In recent years, significant advancements have been made in the field of Lewy body dementia (LBD) treatment, particularly regarding the development of diagnostic tools and treatment modalities.       

• Increasing Aging Population 

As the population ages, the prevalence of LBD is expected to rise, leading to an increased demand for effective treatment options. The aging population is also more likely to experience other age-related health issues, such as Parkinson's disease and Alzheimer's disease, which are risk factors for developing LBD. This demographic shift has significant implications for healthcare systems worldwide, highlighting the need for innovative and accessible LBD treatments. The increasing aging population presents a substantial market opportunity for pharmaceutical companies and healthcare providers to develop and deliver effective treatments for LBD. The global aging population is a significant driver of the Lewy body dementia (LBD) treatment market.

Restraints/Challenges

• Side Effects of Medications  

Some medications commonly used to manage symptoms of LBD, such as antipsychotics and cholinesterase inhibitors, can cause side effects such as sedation, confusion, and movement disorders. These side effects can be particularly problematic for individuals with LBD, as they can exacerbate existing symptoms and impact the quality of life, due to which healthcare providers may be cautious in prescribing these medications, leading to limitations in their use.  One of the challenges in treating Lewy body dementia (LBD) is the potential for significant side effects from medications.            

• Lack of Disease-modifying Therapies

Unlike some other neurodegenerative diseases, such as Alzheimer's disease, there are currently no treatments that can slow or stop the progression of LBD. This is a major limitation in the management of the disease, as current treatments focus primarily on symptom management and do not address the underlying cause of LBD. The lack of disease-modifying therapies is another significant challenge in the treatment of LBD.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In August 2023, a review of Phase II and III trials highlighted the emergence of new drugs for dementia with Lewy bodies (DLB). Despite DLB being associated with faster cognitive decline and having a greater negative impact on patients and caregivers compared to Alzheimer's disease (AD), drug development efforts for DLB lag behind those for AD. Currently, off-label drug options for DLB are limited to symptomatic agents developed for addressing cognitive deficits in AD, motor deficits in Parkinson's disease, or behavioral symptoms in psychiatric diseases. However, recent improvements in DLB diagnosis have sparked a new focus on the development of disease-modifying agents (DMA) for DLB
• In October 2022, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, completed the acquisition of Biohaven Pharmaceuticals Inc. for $11.6 billion. This strategic move is intended to bolster Pfizer's ability to provide innovative treatment solutions worldwide. Biohaven Pharmaceuticals Inc. is dedicated to developing pharmaceuticals for Parkinson's disease, a condition associated with Lewy body dementia, aligning with Pfizer's goal to expand its portfolio of therapies in this therapeutic area

Lewy Body Dementia Treatment Market Scope

The market is segmented on the basis of drug type, application type, mode of purchase, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Cholinesterase Inhibitors
• Antipsychotic Drugs
• Antidepressants
• Benzodiazepine
• Modafinil

Application Type

• Parkinson’s Disease
• Alzheimer’s Disease

Mode of Purchase

• Prescription
• Over the Counter

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Lewy Body Dementia Treatment Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, drug type, application type, mode of purchase, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the market due to factors such as a growing patient population with Lewy body dementia and Parkinson’s disease, an increase in the elderly population, high awareness among the population, and increased affordability of oral medications.

Asia-Pacific is expected to witness significant growth during the forecast period due to ongoing research and development efforts for the treatment of Lewy body dementia, untreated neurological conditions, and numerous opportunities in developing markets.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lewy body dementia treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Lewy Body Dementia Treatment Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

• Amneal Pharmaceuticals LLC. (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Merck & Co Inc. (U.S.)
• Abbott (U.S.)
• B Braun SE (Germany)
• Integra LifeSciences (U.S.)
• Johnson & Johnson Services, Inc. (India)
• Medtronic (Ireland)
• MicroPort Scientific Corporation (China)
• NuVasive, Inc (U.S.)
• Orthofix US LLC (U.S.)
• Perrigo Company plc. (Ireland)
• Stryker Corporation (U.S.)
• Zimmer Biomet (U.S.)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)

SKU-61339